ImmuCell (ICCC) Set to Announce Earnings on Thursday

ImmuCell (NASDAQ:ICCCGet Rating) will post its quarterly earnings results after the market closes on Thursday, August 11th. Persons that are interested in registering for the company’s earnings conference call can do so using this link.

ImmuCell (NASDAQ:ICCCGet Rating) last announced its quarterly earnings data on Thursday, May 12th. The biotechnology company reported $0.09 EPS for the quarter. ImmuCell had a net margin of 5.20% and a return on equity of 3.36%. The business had revenue of $6.00 million during the quarter.

ImmuCell Stock Performance

Shares of NASDAQ ICCC opened at $9.03 on Thursday. The company has a current ratio of 7.78, a quick ratio of 6.32 and a debt-to-equity ratio of 0.30. ImmuCell has a 12 month low of $7.30 and a 12 month high of $10.96. The company has a 50 day simple moving average of $8.43 and a two-hundred day simple moving average of $8.63. The stock has a market cap of $69.92 million, a price-to-earnings ratio of 64.50 and a beta of 0.58.

Institutional Investors Weigh In On ImmuCell

An institutional investor recently raised its position in ImmuCell stock. Vanguard Group Inc. lifted its position in ImmuCell Co. (NASDAQ:ICCCGet Rating) by 22.2% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 204,325 shares of the biotechnology company’s stock after purchasing an additional 37,081 shares during the quarter. Vanguard Group Inc. owned about 2.64% of ImmuCell worth $1,972,000 at the end of the most recent reporting period. 11.94% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, Aegis reiterated a “buy” rating on shares of ImmuCell in a research note on Thursday, June 23rd.

ImmuCell Company Profile

(Get Rating)

ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E.

Read More

Earnings History for ImmuCell (NASDAQ:ICCC)

Want More Great Investing Ideas?

Receive News & Ratings for ImmuCell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuCell and related companies with's FREE daily email newsletter.